Freising, Germany, June 10, 2025 — XL-protein GmbH, a leader in biopolymer technology for optimizing how drugs behave in the body, today announced a global agreement with Grifols, a multinational healthcare company and a top producer of plasma-derived therapies, to license, develop, and commercialize a new, long-acting biopharmaceutical.

This partnership allows XL-protein to use its proprietary PASylation^® technology, already in clinical trials, to prolong the effects of Grifols’ treatments, leading to more effective and longer-lasting results. XL-protein will support early-stage development, while Grifols will handle further development, manufacturing, and marketing of the improved biologic.

According to the agreement, XL-protein will receive an initial payment and additional payments upon reaching preclinical, clinical, regulatory, and commercial milestones. They will also receive ongoing royalties based on sales of the resulting marketed treatments. Grifols gains exclusive worldwide marketing rights. Further financial details remain confidential.

Dr. Jörg Schüttrumpf, Chief Scientific Innovation Officer at Grifols, stated that Grifols is dedicated to ongoing innovation in its therapeutic offerings, both in creating novel therapies and enhancing existing ones for patients. He added they are eager to collaborate with XL-protein and combine their scientific expertise in this important endeavor.

Dr. Michaela Gebauer, Managing Director of XL-protein, expressed excitement about working with Grifols to improve the performance of their treatments. Uli Binder, Managing Director of XL-protein, added that this collaboration highlights the potential of their PASylation technology, alongside other PASylated drugs in development, to create significant value for Grifols.

About Grifols S.A.
Grifols, a global healthcare company established in Barcelona in 1909, is dedicated to enhancing global health and well-being. As a leading provider of essential plasma-derived medicines and transfusion medicine, Grifols develops, manufactures, and delivers innovative healthcare solutions and services in over 110 countries.

About XL-protein GmbH
XL-protein, a privately held biotech firm located near Munich, Germany, utilizes its proprietary PASylation^® technology, which is in clinical development, to create biologics with extended half-lives and enhanced activity in the body. PASylation is an entirely biological technology applicable to both approved biopharmaceuticals for creating improved versions (biobetters) and innovative therapeutic proteins, peptides, or small molecule drugs. This allows for less frequent and lower doses, along with improved patient tolerance, whether administered systemically or in the eye.

Contact:
XL-protein GmbH
Uli Binder (Managing Director)
Phone: +49-8161-53730-90
E-Mail: bd@xl-protein.com

“`